-
From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That’s why we’re expanding and consolidating outpatient...
Learn more
-
Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers...
Learn more
-
A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer.
Learn more
-
Walter J. Urba, M.D., Ph.D.,
Member, director and endowed chair, Earle A. Chiles Research Institute, Providence Cancer Institute
The Earle A. Chiles Research Institute, a division of Providence Cancer Institute at the...
Learn more
-
In his lifetime and through his estate, the late Robert W. Franz gave close to $40 million to Providence Portland Medical Foundation. Providence Cancer Institute has been renamed in his honor.
Learn more
-
Phase I studies are the foundation for advancing cancer treatment with new agents and combinations of therapies. Providence Cancer Institute is often able to offer patients first-in-human clinical trials of novel cancer...
Learn more
-
A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer.
The Phase 2 study, newly underway at Providence Cancer Institute, is led by Kristina Young, M.D., Ph.D., who was recognized in 2016...
Learn more
-
With the release of her book Patient 71, Australia native Julie Randall has given cancer patients across the globe hope for life after cancer. Her remarkable story of overcoming stage IV metastatic melanoma was featured in...
Learn more
-
Known as "Patient 71," persistence paid off for Australian cancer patient Julie Randall
Learn more about her story ›
She now devotes her time to sharing her inspirational story and spreading a word of hope to...
Learn more
-
The Earle A. Chiles Research Institute, a division of Providence Cancer Center in Portland, Ore., was well-represented at the 2017 annual meeting of the American Society of Clinical Oncology held June 2-6 in Chicago, Ill.
Learn more
-
It has been a busy and exciting start to 2017 for immunotherapy researcher Eric Tran, Ph.D., and it could make a great difference in the lives of people fighting cancer.
Learn more
-
More than 20 studies of promising new therapies for lung cancer patients are open now at Providence Cancer Center, including studies of targeted therapies and novel immunotherapy combinations.
Learn more
-
First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference
NORCROSS, Ga. (February 7, 2017) – Galectin Therapeutics Inc. (NASDAQ: GALT), the...
Learn more
-
Immunotherapy is a treatment approach that harnesses the immune system to recognize, attack and eliminate cancer.
The opportunity to conduct immunotherapy research for breast cancer patients is what drew medical oncologist...
Learn more
-
Patients with a variety of cancer types are eligible to receive new and promising treatments when they participate in Phase I research studies at Providence Cancer Center.
Learn more
-
Providence physicians and scientists have been leading the way in melanoma research and treatment for more than 20 years. Our findings have resulted in new ways to boost immune response, which has improved the standard of...
Learn more
-
Providence Oral, Head and Neck Cancer Clinic offers world-class care for patients with benign and malignant tumors of the oral cavity (mouth), tongue, pharynx (throat), larynx (voice box), nose, paranasal sinuses, salivary...
Learn more
-
Providence Cancer Center is actively involved in gastrointestinal cancer research, focusing our attention on cancers of the upper (esophagus and stomach), middle (pancreas, liver, gall bladder, bile ducts and small...
Learn more
-
The National Institutes of Health has awarded two significant grants to Providence Cancer Center researchers
Learn more
-
An unprecedented international collaboration promises to take cancer treatment research to a new level and allow substantially more patients at Providence Cancer Center to take part in clinical trials every year.
Learn more
-
Robert W. Franz, a supporter of cancer research at Providence and philanthropic leader here for more than 30 years, passed away Aug. 9 at Providence Portland Medical Center.
Learn more
-
The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical...
Learn more
-
More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing...
Learn more
-
We mourn the passing of Earle M. Chiles, 83, a long-time champion and supporter of providing exceptional health care for Providence patients in Oregon.
Learn more
-
Excited by the promise and power of immunotherapy research, Providence Cancer Center supporters raised nearly $1 million in the month of May, with most of that coming at the 2016 Creating Hope through Innovation Dinner May...
Learn more
-
Just a year into her career as a Providence Cancer Center radiation oncologist and scientist, Kristina Young, M.D., Ph.D., has been recognized as one of 15 most promising young researchers in the nation by the Sidney...
Learn more
-
Providence researchers have identified an immunotherapy approach that synergizes with radiation so well it not only eliminated the tumor in most preclinical models with pancreatic cancer, it found and destroyed distant,...
Learn more
-
Providence Cancer Center researchers might have identified how to determine if a patient with advanced melanoma will likely respond to a certain immunotherapy treatment.
Learn more
-
A breakthrough drug for treating the most common type of lung cancer was just approved by the Food and Drug Administration ahead of schedule following two successful clinical trials, including one that involved patients at...
Learn more
-
The first patients were treated with the human version in clinical trials, including at Providence Cancer Center.
Learn more
-
The Oregon Historical Society recognized Walter J. Urba, M.D., Ph.D., as a 2014 Oregon History Maker at its Oct. 5 awards dinner, referencing him as a “cancer warrior.”
Learn more
-
Cancer patients in Oregon, Washington and three other Western states will receive improved access to care and clinical trials as a result of a new $6.6 million grant from the National Cancer Institute’s Community...
Learn more
-
Groundbreaking research at Providence Cancer Center is looking for ways to save the lives of people with leukemia and lymphoma. One local man talks about his choice to participate in a clinical trial to help further the...
Learn more
-
Featured in the July issue of the Oregon Business Magazine, Dr. Walter Urba – medical oncologist and director of the Robert W. Franz Center Research Center at Providence Cancer Center – discusses the impact of...
Learn more
-
Diagnosed with metastatic melanoma, a local man was facing an early death. Now, seven years later, he’s beating the odds and spreading the word about skin cancer prevention and a clinical trial involving...
Learn more
-
In the cover story of the July 11, 2014 issue, the Portland Business Journal explores the current state of cancer treatments and the role Portland researchers are playing in new research.
Learn more
-
In a significant show of support for immunotherapy research in the treatment of cancer, the National Institutes of Health has awarded a $1.6 million, five-year grant to Providence Cancer Center researcher Michael Gough,...
Learn more
-
Todd Crocezni, M.D., director of gastrointestinal oncology research at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, is awarded the 2014 Fredman Family...
Learn more
-
In 2005, Providence Cancer Center spun off a biotechnology startup to develop and commercialize several promising cancer vaccines and to take advantage of federal grant money available for innovative science and technology...
Learn more
-
The journal Science has identified immunotherapy as the Breakthrough of the Year, and although the accompanying article doesn’t name Providence Cancer Center specifically, the Portland-based center is a leader in the...
Learn more